Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
McKinsey
McKesson
Moodys

Last Updated: September 25, 2022

NOURESS Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


Which patents cover Nouress, and when can generic versions of Nouress launch?

Nouress is a drug marketed by Baxter Hlthcare Corp and is included in one NDA. There are twelve patents protecting this drug.

This drug has one patent family member in one country.

The generic ingredient in NOURESS is cysteine hydrochloride. There are fourteen drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the cysteine hydrochloride profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Nouress

A generic version of NOURESS was approved as cysteine hydrochloride by DR REDDYS LABS SA on April 8th, 2022.

  Try it Free

Summary for NOURESS
International Patents:1
US Patents:12
Applicants:1
NDAs:1
Finished Product Suppliers / Packagers: 1
Formulation / Manufacturing:see details
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for NOURESS
What excipients (inactive ingredients) are in NOURESS?NOURESS excipients list
DailyMed Link:NOURESS at DailyMed
Drug patent expirations by year for NOURESS

US Patents and Regulatory Information for NOURESS

NOURESS is protected by twelve US patents.

Patents protecting NOURESS

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION

Cysteine composition and injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Cysteine composition and injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF INTRAVENOUSLY ADMINISTERING A DILUTED CYSTEINE HYDROCHLORIDE SOLUTION TO A NEONATE IN NEED THEREOF

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
Patented Use: METHOD OF USING L-CYSTEINE IN AN ADMIXTURE FOR TREATING PATIENTS NEEDING PARENTERAL NUTRITION

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Cysteine composition and injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Stable, highly pure L-cysteine compositions for injection and methods of use
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Cysteine composition and injection
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
Baxter Hlthcare Corp NOURESS cysteine hydrochloride SOLUTION;INTRAVENOUS 212535-001 Dec 13, 2019 DISCN Yes No See Plans and Pricing See Plans and Pricing Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for NOURESS

See the table below for patents covering NOURESS around the world.

Country Patent Number Title Estimated Expiration
Canada 3070798 COMPOSITION DE CYSTEINE ET INJECTION (CYSTEINE COMPOSITION AND INJECTION) See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for NOURESS

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0107734 93C0042 Belgium See Plans and Pricing PROD. NAME TETRAKIS (2-METHOXY-ISOBUTYL-ISONITRILE). CUIVRE (I) TETRAFLUOROBORATE, DIHYDRATE DE CHLORURE STANNEUX, CHLORHYDRATE DE L-CYSTEINE (MONOHYDRATE); REG NO/DATE 923 IS 3 F 12/ 19900924 ; FIRST REG CC NO DATE IE PA 200/9/1 19900817
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Johnson and Johnson
Colorcon
Mallinckrodt
Dow
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.